当前位置: 首页 > 期刊 > 《中国医学创新》 > 2021年第18期
编号:185898
维格列汀联合胰岛素治疗对肥胖型2型糖尿病患者HbA1c、vaspin水平及胰岛β细胞功能的影响
http://www.100md.com 2021年3月27日 中国医学创新 2021年第18期
糖化血红蛋白,不良反应
     贺五风 欧阳娟 杨丽华

    【关键词】 肥胖型2型糖尿病 维格列汀 胰岛素 糖化血红蛋白 胰岛β细胞功能 不良反应

    [Abstract] Objective: To investigate the effects of Vildagliptin combined with Insulin on blood glucose and islet β-cell function in patients with obese type 2 diabetes mellitus (T2DM). Method: A total of 86 obese T2DM patients admitted to our hospital from March 2018 to March 2020 were selected. According to random number table method, they were divided into control group and observation group, 43 cases in each group. The control group was treated with Insulin, and the observation group was additively treated with Vildagliptin. Blood glucose related indexes, islet β cell function (HOMA-β), serine protease inhibitor (vaspin) were compared between two groups, the incidence of adverse reactions in two groups were observed. Result: At 12 weeks after treatment ......

您现在查看是摘要页,全文长 9948 字符